MedPath

Percutaneous Plug-based Femoral Arteriotomy Closure Device Use in Surgery for Acute Type A Aortic Disection

Completed
Conditions
Aortic Dissection
Registration Number
NCT05482555
Lead Sponsor
Karolinska University Hospital
Brief Summary

A single-center prospective study. Patients undergoing surgery for acute type A aortic dissection with femoral arterial cannulation between 2017 and 2022 at the Karolinska University Hospital in Stockholm, Sweden are eligible. Femoral cannulation was performed either with surgical cut-down and arterial puncture under direct vision or percutaneously with planned percutaneous arteriotomy closed using a plug-based arteriotomy closure device (MANTA, Essential Medical Inc., Malvern, Pennsylvania). Data regarding preoperative clinical characteristics and operative details were obtained by medical records review.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
171
Inclusion Criteria
  • Operated for acute type A aortic dissection between 2017 and 2022 at the Karolinska University Hospital in Stockholm, Sweden.
Exclusion Criteria
  • Non-femoral arterial cannulation
  • Concomitant femoro-femoral bypass
  • Conversion to ECMO with arterial inflow in the previously cannulated femoral artery
  • Death within 30 days from procedure
  • Loss to follow-up

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Femoral access site complicationDuring the first 8 weeks after surgery

Seroma, wound infection, or nerve injury

Secondary Outcome Measures
NameTimeMethod
Femoral artery complicationDuring the first 3 years after surgery

Pseudoaneurysm, local dissection, stenosis, intermittent claudication, or vascular closure device failure

Trial Locations

Locations (1)

Department of Cardiothoracic Surgery, Karolinska University Hospital

🇸🇪

Stockholm, Sweden

Department of Cardiothoracic Surgery, Karolinska University Hospital
🇸🇪Stockholm, Sweden

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.